Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

BostonGene to Present Multiple Abstracts at the 2019 American Society of Hematology (ASH) Annual Meeting


BostonGene Corporation (BostonGene), a Boston-based biomedical software company, today announced that as a result of its collaborations, multiple abstracts have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, Florida. In addition, BostonGene will exhibit at booth #152 in Hall B.

The presentations will provide results demonstrating the role of the tumor microenvironment in cancer classification and treatment outcomes. By combing whole exome and transcriptome sequencing analysis, the significance of stromal and immune compartments of microenvironment in therapeutically relevant categories of Mantle Cell Lymphomas and Diffuse Large B-Cell Lymphoma (DLBCL) is identified.

POSTER PRESENTATION

Sunday, December 8, 2019: 6:00 PM - 8:00 PM in Hall B, Level 2

ORAL PRESENTATION

Monday, December 9, 2019: 10:45 AM in Tangerine 2 (WF2), Level 2

Additional information on abstracts for the ASH Annual Meeting can be found here: https://www.hematology.org/Annual-Meeting/.

"We are excited to share our success as a strategic collaborator with two of the leading cancer centers in the world at this year's ASH event. We look forward to showcasing our innovative platform that will ultimately impact and improve cancer patients' chances for survival," said Andrew Feinberg, President & CEO at BostonGene.

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene's unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene's mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.


These press releases may also interest you

at 01:00
XenZone, the UK's largest provider of online mental health services - including the renowned Kooth service for children and young people - has appointed Tim Barker, previously at DataSift and Salesforce, as its new chief executive.     As a pioneer...

at 01:00
Korea Centers for Disease Control & Prevention notified Seegene Inc. (096530.KQ) that Korea Ministry of Food and Drug Safety (MFDS; Former KFDA) approved its novel coronavirus (COIVD-19) Real-time PCR assay for the Emergency Use, following the recent...

at 01:00
Urinary incontinence is a common ailment that many women face. This life altering and often embarrassing condition can be treated. Women's Excellence offers a variety of minimally invasive treatment solutions for women suffering from urinary leakage....

at 00:00
RidgeCrest Herbals is starting out 2020 right, with a new award for its most popular product, ClearLungs Original. They are thrilled that the #1 selling lung-support product in the herbal industry has won the Taste For Life Essentials Award,...

17 fév 2020
A January 18 article on Yahoo Sports reports on the gruesome injury that Las Vegas Golden Knights center Paul Stastny sustained as he was hit in the face with a high stick, knocking out several of his teeth and dispersing enough blood to warrant the...

17 fév 2020
Cybersecurity specialists hired by NCH recently wrapped up their investigation into an email phishing attack against NCH.  On or around June 14, 2019, NCH became aware of suspicious activity related to its human resources, timekeeping, and payroll...



News published on 21 november 2019 at 10:25 and distributed by: